HUP0301719A2 - Szorongásos neurózis vagy depresszió kezelésére szolgáló gyógyszerkészítmény és piperazinszármazékok - Google Patents

Szorongásos neurózis vagy depresszió kezelésére szolgáló gyógyszerkészítmény és piperazinszármazékok

Info

Publication number
HUP0301719A2
HUP0301719A2 HU0301719A HUP0301719A HUP0301719A2 HU P0301719 A2 HUP0301719 A2 HU P0301719A2 HU 0301719 A HU0301719 A HU 0301719A HU P0301719 A HUP0301719 A HU P0301719A HU P0301719 A2 HUP0301719 A2 HU P0301719A2
Authority
HU
Hungary
Prior art keywords
group
general formula
hydrogen atom
naphthyl
depression
Prior art date
Application number
HU0301719A
Other languages
English (en)
Inventor
Shigeyuki Chaki
Takaaki Ishii
Atsuro Nakazato
Shin-Ichi Ogawa
Taketoshi Okubo
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of HUP0301719A2 publication Critical patent/HUP0301719A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány szorongásos neurózis vagy depresszió kezelésére szolgálógyógyászati készítményekre vonatkozik, amelyek hatóanyagként MC4receptor antagonistát tartalmaznak. A találmány vonatkozik továbbá az(1) általános képletű piperazinszármazékokra és sóira - a képletbenAr1 jelentése fenil-, szubsztituált fenil-, naftil- vagy szubsztituáltnaftil-, Ar2 jelentése naftil-, szubsztituált naftil-, kinolil- vagyegy (a) általános képletű csoport, ahol R4 jelentése hidrogénatom vagyhalogénatom és X-Y jelentése CH-NH, CH-O, CH-S vagy N-O csoport, vagyegy (b) általános képletű csoport, ahol R5 jelentése hidrogénatom,hidroxilcsoport, vagy 1-10 szénatomos alkoxicsoport, R1 jelentésehidrogénatom, 1-10 szénatomos alkil-, 3-8 szénatomos cikloalkil-, 3-10szénatomos alkenil-, fenil-, 1-cianoetil-, pirimidin-2-il- vagyamidilcsoport, R2 és R3 jelentése azonosan vagy különbözőenhidrogénatom vagy 1-10 szénatomos alkilcsoport, A-B jelentése N-CH2,CH-CH2, C(OH)-CH2 vagy C=CH, T1 jelentése vegyértékkötés, -N(R6)-általános képletű csoport - ahol R6 jelentése hidrogénatom vagy 1-10szénatomos alkilcsoport, -O-, -CH=CH- vagy -C(=O); és n értéke 1-10,ha T1 jelentése vegyértékkötés, -CH=CH-vagy -C(=O)- és n értéke 2-10,ha T1 jelentése -N(R6)-vagy -O-. A fenti (1) általános képletűvegyületek MC4 receptor antagonista hatásúak. Ó
HU0301719A 2000-06-27 2001-06-27 Szorongásos neurózis vagy depresszió kezelésére szolgáló gyógyszerkészítmény és piperazinszármazékok HUP0301719A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000192856 2000-06-27
PCT/JP2001/005524 WO2002000259A1 (fr) 2000-06-27 2001-06-27 Agent therapeutique contre l'anxiete nevrotique ou la depression et derive de piperazine

Publications (1)

Publication Number Publication Date
HUP0301719A2 true HUP0301719A2 (hu) 2003-09-29

Family

ID=18691931

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301719A HUP0301719A2 (hu) 2000-06-27 2001-06-27 Szorongásos neurózis vagy depresszió kezelésére szolgáló gyógyszerkészítmény és piperazinszármazékok

Country Status (22)

Country Link
US (1) US6949552B2 (hu)
EP (1) EP1295608A4 (hu)
JP (1) JP5002881B2 (hu)
KR (1) KR20030013470A (hu)
CN (1) CN1438897A (hu)
AU (2) AU6634201A (hu)
BG (1) BG107371A (hu)
BR (1) BR0111976A (hu)
CA (1) CA2413506A1 (hu)
CZ (1) CZ20024165A3 (hu)
EA (2) EA200500087A1 (hu)
EE (1) EE200200717A (hu)
HR (1) HRP20030056A2 (hu)
HU (1) HUP0301719A2 (hu)
IL (1) IL153706A0 (hu)
MX (1) MXPA02012707A (hu)
NO (1) NO20026122L (hu)
NZ (1) NZ523800A (hu)
PL (1) PL360286A1 (hu)
SK (1) SK18322002A3 (hu)
WO (1) WO2002000259A1 (hu)
ZA (1) ZA200210386B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL360286A1 (en) 2000-06-27 2004-09-06 Taisho Pharmaceutical Co.Ltd. Remedial agent for anxiety neurosis or depression and piperazine derivative
EP1425029A4 (en) 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
JPWO2003053927A1 (ja) * 2001-12-21 2005-04-28 大正製薬株式会社 ピペラジン誘導体
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AR054435A1 (es) * 2005-04-04 2007-06-27 Takeda Pharmaceutical Agente para profilaxis o terapia contra la depresion o desorden de ansiedad
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008039863A2 (en) * 2006-09-27 2008-04-03 Braincells, Inc. Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders
EP2072050A1 (en) 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
JP2013503835A (ja) 2009-09-07 2013-02-04 ヴィフォール （インターナショナル） アクチェンゲゼルシャフト 新規なエタンジアミン系ヘプシジン拮抗薬
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1317053A (fr) * 1961-03-17 1963-02-01 Soc Ind Fab Antibiotiques Sifa Nouveaux dérivés de la pipérazine, et procédé de préparation
CA918659A (en) * 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
FR2601364B1 (fr) * 1986-07-09 1988-10-21 Adir Nouveaux derives de la piperazine dione-2,6, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9021453D0 (en) * 1990-10-03 1990-11-14 Wyeth John & Brother Ltd Piperazine derivatives
JPH0641071A (ja) * 1991-09-06 1994-02-15 Taisho Pharmaceut Co Ltd インドール酢酸エステル誘導体
GB9200293D0 (en) * 1992-01-08 1992-02-26 Wyeth John & Brother Ltd Piperazine derivatives
SE9700620D0 (sv) * 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
PL360286A1 (en) 2000-06-27 2004-09-06 Taisho Pharmaceutical Co.Ltd. Remedial agent for anxiety neurosis or depression and piperazine derivative

Also Published As

Publication number Publication date
EP1295608A4 (en) 2004-03-31
EA200300071A1 (ru) 2003-06-26
EP1295608A1 (en) 2003-03-26
HRP20030056A2 (en) 2005-02-28
BG107371A (bg) 2003-08-29
PL360286A1 (en) 2004-09-06
AU2001266342B2 (en) 2005-01-27
NO20026122D0 (no) 2002-12-19
BR0111976A (pt) 2003-12-09
WO2002000259A1 (fr) 2002-01-03
EA005737B1 (ru) 2005-06-30
SK18322002A3 (sk) 2003-09-11
NO20026122L (no) 2003-02-25
IL153706A0 (en) 2003-07-06
US6949552B2 (en) 2005-09-27
US20030186992A1 (en) 2003-10-02
EA200500087A1 (ru) 2005-06-30
CN1438897A (zh) 2003-08-27
KR20030013470A (ko) 2003-02-14
CA2413506A1 (en) 2002-12-20
EE200200717A (et) 2004-08-16
ZA200210386B (en) 2004-02-10
JP5002881B2 (ja) 2012-08-15
AU6634201A (en) 2002-01-08
CZ20024165A3 (cs) 2004-03-17
NZ523800A (en) 2005-02-25
MXPA02012707A (es) 2003-04-25

Similar Documents

Publication Publication Date Title
HUP0301719A2 (hu) Szorongásos neurózis vagy depresszió kezelésére szolgáló gyógyszerkészítmény és piperazinszármazékok
AR057107A2 (es) Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos
AR076860A1 (es) Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
BR0308816A (pt) Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
HUP0303339A2 (hu) Heteroaril-karbamid neuropeptid Y Y5 receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
AR033306A1 (es) Compuestos
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
BR0112856A (pt) Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
PE20020483A1 (es) Peptidos ciclicos selectivos como agonistas de los receptores de melanocortina 4
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
RU2006135111A (ru) Производные тиазола
FR2842804B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
AR062221A1 (es) Imidazolidina-2,4- dionas sustituidas con arilaminoarilalquilo, medicamentos que comprenden estos compuestos y su uso
AR036366A1 (es) Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
AR070579A1 (es) Imidazolina -2,4- dionas sustituidas procesos para su preparacion medicamentos que comprenden estos compuestos y uso de los mismos
KR950032267A (ko) 11,21-비스페닐-19-노르프레그난 유도체
AR034174A1 (es) Compuestos de benzoxazinona, procedimiento para su preparacion, composiciones farmaceuticas que lo comprenden, procedimiento para la preparacion de tales composiciones, y el uso de dichos compuestos o composiciones en la fabricacion de medicamentos
MXPA04002495A (es) Compuestos de imidazopiridin como moduladores del receptor 5-ht4.
TR199801218T2 (xx) Takikinin antagonistleri olarak N-asil-2-ikameli-4-(Benzimidazolil-ya da imidazopiridinil-ikameli art�klar)-piperidinler.
AR034700A1 (es) Derivados de pirimidina,procesos para prepararlos, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos para la elaboracion de medicamentos
AR024840A1 (es) Compuestos de 5ht1 para terapia antidepresiva; composiciones farmaceuticas y su uso en la preparacion de medicamentos.
PE20030719A1 (es) Derivados de 8-[bis(2-halofenil)metil]-3-heteroaril-8-azabiciclo[3.2.1] octan-3-ol como agonistas del receptor de nociceptina orl-1

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees